Ignite Creation Date:
2024-05-05 @ 12:09 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00266565
Status:
COMPLETED
Last Update Posted:
2020-07-29
First Post:
2005-12-15
Brief Title:
Anti-Interleukin-5 IL-5 Study for Hypereosinophilic Syndrome
Sponsor:
Childrens Hospital Medical Center Cincinnati
Organization:
Childrens Hospital Medical Center Cincinnati
Study Overview
Official Title:
A Phase III Study of the Effect of Intravenous Anti-IL-5 Mepolizumab SB 240563 on the Outcome and Management of Hypereosinophilic Syndromes
Status:
COMPLETED
Status Verified Date:
2020-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Toxicity of anti-IL-5
Detailed Description:
The purpose of the study is to assess the toxicity of anti-IL-5 and to see whether it lowers peripheral blood eosinophils andor tissue and whether it has a steroid andor interferon sparing effect
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| FD-R-002396 | OTHER | Cincinnati Childrens | None |